CAS 1223498-69-8: Roniciclib

Roniciclib (BAY 1000394) is a potent pan-CDK inhibitor and a novel oral cytotoxic agent. Roniciclib inhibits the activity of cell-cycle CDKs CDK1, CDK2, CDK3, CDK4, and of transcriptional CDKs CDK7 and CDK9 with IC(50) values in the range between 5 and 25 nmol/L.

BAY 1000394 is an investigational drug compound that functions as an oral anticoagulant. It originates from synthetic chemical processes designed to create potent and selective inhibitors of specific targets within the coagulation cascade. The mode of action involves the inhibition of Factor Xa, an essential enzyme in the coagulation pathway that catalyzes the conversion of prothrombin to thrombin, ultimately leading to fibrin clot formation. By targeting Factor Xa, BAY 1000394 effectively reduces the generation of thrombin, thereby diminishing the formation of pathologic clots without markedly altering existing fibrinogen levels. The applications of BAY 1000394 are predominantly in the field of thromboprophylaxis and thromboembolic event management. It has potential utility in preventing stroke and systemic embolism in patients with atrial fibrillation, as well as in the prophylaxis and treatment of venous thromboembolism (VTE) and deep vein thrombosis (DVT). Furthermore, its oral administration route offers a more convenient option compared to parenteral anticoagulants, which may enhance patient compliance in chronic treatment settings. Ongoing studies are necessary to elucidate its full clinical potential and safety profile.

Roniciclib